Head-To-Head Survey: Aligos Therapeutics (NASDAQ:ALGS) vs. Longeveron (NASDAQ:LGVN)

Aligos Therapeutics (NASDAQ:ALGS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Aligos Therapeutics and Longeveron, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1	0	2	0	2.33
Longeveron	1	0	2	0	2.33

Aligos Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 278.79%. Longeveron has a consensus price target of $6.50, indicating a potential upside of 1,085.70%. Given Longeveron’s higher possible upside, analysts plainly believe Longeveron is more favorable than Aligos Therapeutics.

Risk & Volatility

Aligos Therapeutics has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.

Insider and Institutional Ownership

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 4.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Longeveron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Aligos Therapeutics and Longeveron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-3,267.65%	-39.35%	-22.09%
Longeveron	-1,485.25%	-138.44%	-108.46%

Earnings & Valuation

This table compares Aligos Therapeutics and Longeveron”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$3.94 million	14.42	-$131.21 million	($19.76)	-0.47
Longeveron	$2.39 million	4.89	-$15.97 million	($1.06)	-0.52

Longeveron has lower revenue, but higher earnings than Aligos Therapeutics. Longeveron is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Aligos Therapeutics beats Longeveron on 7 of the 12 factors compared between the two stocks.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.